

# Key references

---

## Myeloma Nurse Guide

General references for the nurse guide series, and those specific to each guide, are provided below for further reading.

### General references

- ▣ National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [https://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/ctc.htm#ctc\\_50](https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50)
- ▣ National Institute for Health and Care Excellence (2016) NICE Guidelines (NG35) Myeloma: diagnosis and Management. NICE: London <https://www.nice.org.uk/guidance/ng35>
- ▣ Osborne et al. (2015) Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS) BMC Cancer. 15 280. DOI: [10.1186/s12885-015-1261-6](https://doi.org/10.1186/s12885-015-1261-6)
- ▣ Sive et al. (2021) Guidelines on the diagnosis, investigation and initial treatment of myeloma. BJHaem 193, 245–268. DOI: [10.1111/bjh.14514](https://doi.org/10.1111/bjh.14514)
- ▣ Snowden et al. (2017) Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. BJHaem 176, 888–907. DOI: [10.1111/bjh.14514](https://doi.org/10.1111/bjh.14514)
- ▣ Snowden et al. (2011) Guidelines for supportive care in multiple myeloma. BJHaem 154, 76–103. DOI: [10.1111/j.1365-2141.2011.08574.x](https://doi.org/10.1111/j.1365-2141.2011.08574.x)

## AL amyloidosis

- ▣ Chung et al (2008) STOP questionnaire: a tool to screen patients for obstructive sleep apnea, *Anesthesiology* 108 812-21. DOI: [10.1097/ALN.0b013e31816d83e4](https://doi.org/10.1097/ALN.0b013e31816d83e4)
- ▣ Fogaren et al (2022) Understanding Amyloidosis: Unravelling the complexities and therapeutic approaches for oncology nurses, *Clin J of Oncology Nursing* 26(4) 421-432. DOI: [10.1188/22.CJON.421-432](https://doi.org/10.1188/22.CJON.421-432)
- ▣ Gillmore et al (2015) Guidelines on the diagnosis and investigation of AL amyloidosis, *BJ Haem* 168(2) 207-218. DOI: [10.1111/bjh.13156](https://doi.org/10.1111/bjh.13156)
- ▣ Lousada & Boedicker (2020) the impact of AL amyloidosis: the patient experience, *Haematol Oncol Clin North Am* 34(6) 1193-1203. DOI: [10.1016/j.hoc.2020.08.003](https://doi.org/10.1016/j.hoc.2020.08.003)
- ▣ Maroun BZ Allam S and Chaulagain CP (2022) Multidisciplinary supportive care in systemic light chain amyloidosis, *Blood Research* 57(2) 106-16. DOI: [10.5045/br.2022.2021227](https://doi.org/10.5045/br.2022.2021227)
- ▣ Myeloma UK. Facts about AL amyloidosis. <https://myeloma.org.uk/understanding-myeloma/related-conditions/al-amyloidosis/>
- ▣ Palladini G, Milani P, Merlini G. (2020) Management of AL amyloidosis in 2020, *Blood* 136 2620-7. DOI: [10.1182/blood.2020006913](https://doi.org/10.1182/blood.2020006913)
- ▣ Ramasamy K, Lonial S. (2017) *Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias*, 2nd ed. Health Press Ltd. DOI: [10.1159/isbn.978-1-910797-38-9](https://doi.org/10.1159/isbn.978-1-910797-38-9)
- ▣ Wechalekar et al (2015) Guidelines on the management of AL amyloidosis, *BJ Haem* 168 (2) 186-206. DOI: [10.1111/bjh.13155](https://doi.org/10.1111/bjh.13155)
- ▣ Wechalekar et al (2022) Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group, *Amyloid* 30(1) 3-17. DOI: [10.1080/13506129.2022.2093635](https://doi.org/10.1080/13506129.2022.2093635)

## Bisphosphonates

- ▣ Anderson et al. (2018) Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Onc.* 36(8) 812–818. DOI: [10.1200/jco.2017.76.6402](https://doi.org/10.1200/jco.2017.76.6402)
- ▣ Medicines and Healthcare products Regulatory Agency (2014) Bisphosphonates: osteonecrosis of the jaw. (Accessed August 2022) <https://www.gov.uk/drug-safety-update/bisphosphonates-osteonecrosis-of-the-jaw>
- ▣ Morgan et al. (2010) National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet.* 376(9757) 1989–99. DOI: [10.1016/s0140-6736\(10\)62051-x](https://doi.org/10.1016/s0140-6736(10)62051-x)
- ▣ Raje et al. (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. *The Lancet Onc.* 19(3) 370–381. DOI: [10.1016/s1470-2045\(18\)30072-x](https://doi.org/10.1016/s1470-2045(18)30072-x)

## Bone disease

- ▣ Chantry et al. (2017) Guidelines for the use of imaging in the management of patients with myeloma. *BJHaem*. 178, 380–393. DOI: [10.1111/bjh.14827](https://doi.org/10.1111/bjh.14827)
- ▣ National Institute for Health and Care Excellence (2008) Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75). NICE: London. <https://www.nice.org.uk/guidance/cg75>
- ▣ Terpos et al. (2021) Treatment of multiple myeloma related-bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. *Lancet Oncol*. 22(3), e119–e130. DOI: [10.1016/s1470-2045\(20\)30559-3](https://doi.org/10.1016/s1470-2045(20)30559-3)

## Emotional and psychological changes

- ▣ Kelly and Dowling (2011) Patients' lived experience of myeloma. *Nurs Stand*. 25(28) 38–44. DOI: [10.7748/ns2011.03.25.28.38.c8397](https://doi.org/10.7748/ns2011.03.25.28.38.c8397)
- ▣ Kroenke, K, Spitzer, RL and Williams, J.B., The PHQ-9: validity of a brief depression severity measure. 2001, *J Gen Intern Med* 16(9) 606–13. DOI: [10.1046/j.1525-1497.2001.016009606.x](https://doi.org/10.1046/j.1525-1497.2001.016009606.x)
- ▣ MIND. What are the symptoms of depression? (Accessed 2022) <https://www.mind.org.uk/information-support/types-of-mental-health-problems/depression/symptoms/>
- ▣ Molassiotis et al. (2011) Living with multiple myeloma: experiences of patients and their informal caregivers. *Supportive Care in Cancer*. 19(1) 101–111. DOI: [10.1007/s00520-009-0793-1](https://doi.org/10.1007/s00520-009-0793-1)
- ▣ National Institute for Health and Care Excellence (2004) Improving supportive and palliative care for adults with cancer: (CSG4) NICE: London. <https://www.nice.org.uk/guidance/csg4>
- ▣ Spitzer et al. (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 22 166 (10) 1092–7 13. DOI: [10.1001/archinte.166.10.1092](https://doi.org/10.1001/archinte.166.10.1092)
- ▣ Zigmond and Snaith (1983) The Hospital Anxiety and Depression Scale. *Acta Psychiatrica Scandinavica*. 67 361–370. DOI: [10.1111/j.1600-0447.1983.tb09716.x](https://doi.org/10.1111/j.1600-0447.1983.tb09716.x)

## Fatigue

- ▣ Berger et al. (2015) Screening, evaluation, and management of cancer-related fatigue: Ready for implementation to practice? *CA Cancer J Clin*. 65(3) 190–211. DOI: [10.3322/caac.21268](https://doi.org/10.3322/caac.21268)
- ▣ Catamero et al. (2017) Distress, fatigue and sexuality: understanding and treating concerns and symptoms in patients with multiple myeloma. *Clin J Oncol Nurse*. 21(5) 7–19. DOI: [10.1188/17.cjon.s5.7-18](https://doi.org/10.1188/17.cjon.s5.7-18)
- ▣ Coleman et al. (2011) Fatigue, sleep, pain, mood and performance status in patients with multiple myeloma. *Cancer Nursing*. 34(3) 219–227. DOI: [10.1097/ncc.0b013e3181f9904d](https://doi.org/10.1097/ncc.0b013e3181f9904d)
- ▣ Land et al. (2022) Myeloma patients' experiences of a supervised physical activity programme: a qualitative study. *Supportive Care in Cancer*. 30(7) 6273–6286. DOI: [10.1007/s00520-022-07062-x](https://doi.org/10.1007/s00520-022-07062-x)

## Gastrointestinal toxicities

- ▣ Andreyev et al. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. *Lancet Oncol.* 15(10) e447–60. DOI: [10.1016/s1470-2045\(14\)70006-3](https://doi.org/10.1016/s1470-2045(14)70006-3)
- ▣ Bechtel et al. (2014) Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. *Support Care Cancer.* 22(11) 2911–6. DOI: [10.1007/s00520-014-2248-6](https://doi.org/10.1007/s00520-014-2248-6)
- ▣ Pawlyn et al. (2014) Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. *Blood.* 124(15) 2467–8. DOI: [10.1182/blood-2014-06-583302](https://doi.org/10.1182/blood-2014-06-583302)
- ▣ Smith et al. (2008) Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. *Clin J Oncol Nurs.* 12(3) 37–52. DOI: [10.1188/08.cjon.s1.37-51](https://doi.org/10.1188/08.cjon.s1.37-51)

## Myeloma kidney disease

- ▣ Dimopoulos et al. (2016) International Myeloma Working Group Recommendations for the diagnosis and management of myeloma-related renal impairment. *Journal of Clin Onc.* 34 (13) 1544–1557. DOI: [10.1200/jco.2015.65.0044](https://doi.org/10.1200/jco.2015.65.0044)
- ▣ National Institute for Health and Clinical Excellence (2019) Acute kidney injury: prevention, detection and management (NG148). NICE: London. <https://www.nice.org.uk/guidance/ng148>
- ▣ National Institute for Health and Clinical Excellence (2021) Chronic kidney disease: assessment and management (NG203). NICE: London. <https://www.nice.org.uk/guidance/ng203>

## Myelosuppression

- ▣ National Institute for Health and Care Excellence (2012) Neutropenic sepsis: prevention and management in people with cancer (CG151). NICE: London. <https://www.nice.org.uk/guidance/cg151>
- ▣ National Institute for Health and Care Excellence (2014) Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323). NICE: London. <https://www.nice.org.uk/guidance/ta323>

## Oral mucositis

- ▣ European Oral Care in Cancer Group: oral care guidance and support. (Accessed August 2022) <http://www.eocc.co.uk/wp-content/uploads/2018/09/EOCC-English-Guidance.pdf>
- ▣ Quinn (2013) Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. *Eur J Cancer Care (Engl).* 22(5) 564–79. DOI: [10.1111/ecc.12073](https://doi.org/10.1111/ecc.12073)
- ▣ World Health Organisation (1979) WHO Handbook for Reporting results of cancer treatment. WHO: Geneva. <https://apps.who.int/iris/handle/10665/37200>

## Peripheral neuropathy

- ▣ Chaudhry et al. (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. *J Peripher Nerv Syst.* 13(4) 275–82. DOI: [10.1111/j.1529-8027.2008.00193.x](https://doi.org/10.1111/j.1529-8027.2008.00193.x)
- ▣ FACIT.org. FACT-GOG-NTX: functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (Accessed August 2022) <https://www.facit.org/measures/FACT-GOG-NTX>
- ▣ Richardson et al. (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia.* 26(4) 595–608. DOI: [10.1038/leu.2011.346](https://doi.org/10.1038/leu.2011.346)

## Steroids

- ▣ Faiman et al. (2008) Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. *Clin J Oncol Nurse.* 12(3) 53–62. DOI: [10.1188/08.cjon.S1.53-62](https://doi.org/10.1188/08.cjon.S1.53-62)
- ▣ King et al. (2019) The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): feasibility, acceptability, reliability and internal consistency. *Clin Lymphoma Myeloma and Leukemia.* 19(10) e348. DOI: [10.1016/j.clml.2019.09.562](https://doi.org/10.1016/j.clml.2019.09.562)
- ▣ King and Faiman (2017) Steroid -associated side effects: a symptom management update on multiple myeloma treatment. *Clin J Oncol Nurse.* 21(2) 240–249. DOI: [10.1188/17.cjon.240-249](https://doi.org/10.1188/17.cjon.240-249)

## Venous Thromboembolism

- ▣ Fotiou, Favriatopoulou and Terpos (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. *Cancers.* 12, 191. DOI: [10.3390/cancers12010191](https://doi.org/10.3390/cancers12010191)
- ▣ National Institute for Health and Care Excellence (2020) Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158). NICE: London. <https://www.nice.org.uk/guidance/ng158>
- ▣ Sanfilippo et al. (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. *Am J Hematol.* 94(11), 1176–1184. DOI: [10.1002/ajh.25603](https://doi.org/10.1002/ajh.25603)



### Myeloma★Academy

For further nurse guides and other educational resources on myeloma and related conditions:

[academy.myeloma.org.uk](https://academy.myeloma.org.uk)

Published by:	Myeloma UK
Publication date:	August 2022
Last updated:	June 2023
Review date:	December 2024

**Myeloma UK** 22 Logie Mill, Beaverbank Business Park, Edinburgh EH7 4HG

☎ 0131 557 3332 ✉ [myelomauk@myeloma.org.uk](mailto:myelomauk@myeloma.org.uk)

Registered Charity No: SC026116